BioSpace News Archive

While the opioid overdose and death epidemic continues to worsen across the United States, medications such as methadone, buprenorphine and extended-release naltrexone are proven to reduce opioid overdoses by more than 50 percent.

Apnimed announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022.

Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pK a ).

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, 2022, after the market closes.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th.

BriaCell Therapeutics Corp. announces that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.

Novavax, Inc. today announced the initiation of its Phase 2b /3 Hummingbird™ global clinical trial.

GenBody America, LLC, the U.S. affiliate of GenBody, Inc., a South Korean manufacturer of rapid diagnostic tests and reagents for point-of-care applications for COVID-19, today announced that the FDA has granted an extension of the shelf-life for its COVID-19 Ag test from 12 months to 21 months when stored at 2° - 30° C (approx. 35° - 86° F).

Timber Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced the pricing of a public offering of 66,666,667 shares of its common stock and warrants to purchase up to 66,666,667 shares of its common stock at an offering price to the public of $0.12 per share and associated warrant.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces today that it has launched a new website Necrobiosislipoidicastudy.com.